Target intelligence / Profile preview

Filaggrin protein (FLG)

Target
FLG
Molecular classification
Structural protein, Intermediate filament-associated protein, Other
01

Overview

Filaggrin is an intermediate filament-associated structural protein crucial for epidermal differentiation and formation of the skin's protective barrier. Synthesized initially as profilaggrin—a large polyprotein stored in keratohyaline granules—filaggrin is proteolytically processed into functional monomers during terminal differentiation. These monomers aggregate keratin fibers within corneocytes, flattening cells and strengthening intercellular adhesion to create an effective physical barrier against water loss and environmental insults. Subsequent degradation yields hygroscopic amino acids that constitute natural moisturizing factors essential for maintaining hydration and acidic pH on the skin surface. Mutations leading to loss or reduction of functional filaggrin disrupt these processes, resulting in conditions like atopic dermatitis (eczema), ichthyosis vulgaris, increased asthma risk due to compromised epithelial integrity, and potential autoimmune cross-reactivity. While not itself a direct drug target currently, its genetic status serves as an important biomarker for several dermatological diseases[1][2][3][4][5].

Other names
Filament aggregating proteinFLGProfilaggrin (precursor form)
02

Biological functions

Aggregation of keratin intermediate filaments in epidermal cellsFormation and maintenance of the skin barrier (epidermal homeostasis)Regulation of water retention and hydration via breakdown products ("natural moisturizing factor")Maintenance of acidic pH on skin surface ("acid mantle")
03

Disease associations

Atopic dermatitis (eczema)Ichthyosis vulgarisAsthma susceptibility (as a genetic risk modifier)Autoimmune cross-reactivity in rheumatoid arthritis (autoantibodies may recognize citrullinated filaggrin epitopes)
04

Safety considerations

Genetic deficiency leads to impaired skin barrier, increasing susceptibility to allergens, irritants, infections, and dehydration; this presents challenges for topical therapies due to increased absorption/risk of irritationTopical steroids can reduce production of profilaggrin/filaggrin with long-term use, potentially worsening barrier dysfunction in susceptible individuals
05

Biomarkers

Loss-of-function mutations in FLG gene as biomarkers for atopic dermatitis risk/severity and ichthyosis vulgaris diagnosis

Beyond the preview

Go deeper on Filaggrin protein (FLG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Filaggrin protein (FLG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call